Before any antipsychotic, the MN665 Unit 2 analysis screens for delirium and reviews amantadine; only then does it weigh pimavanserin against low-dose clozapine for a composite Parkinson's patient. Searches like "mn 665 unit 2 assignment example", "mn665 unit 2 sample" and "mn665 unit 2 example" land here.
What a finished MN665 Unit 2 complex case analysis looks like
Five parts over roughly five pages. The case summary records the facts that shape everything later: hallucinations for [four] months with insight fading, the infidelity belief for [six] weeks, a Montreal Cognitive Assessment of [23], no fever or infection, and a medication list holding [carbidopa-levodopa], [amantadine] and [trihexyphenidyl] for tremor. Part two rules out delirium with the Confusion Assessment Method and a basic workup. Part three proposes reducing the medicines most likely to provoke psychosis, the anticholinergic first and then amantadine, one at a time with motor function watched. Part four weighs three antipsychotic options if symptoms persist: pimavanserin, which the FDA approved in April 2016 for Parkinson's disease psychosis; clozapine at low doses, supported by two 1999 trials; and quetiapine, widely used despite weak trial support. Part five sets monitoring.
How a MN665 Unit 2 example is structured
The analysis is sequenced as a clinician would have to act, so the antipsychotic decision sits fourth. Every stage closes on a stated result that would stop the sequence: a positive delirium screen redirects to its cause, and hallucinations that fade after the anticholinergic is withdrawn end the case without any new drug. Medication reductions are framed as proposals for his neurologist, since motor control belongs to that clinician and a psychiatric plan cannot buy quieter hallucinations with a worse gait. The option comparison scores all three agents on four fixed criteria: evidence in this disorder, motor effects, monitoring burden and cost. Pimavanserin is chosen, with its QT warning and its onset over weeks spelled out. Clozapine is kept as the named fallback, and the blood count monitoring that makes it harder for this household is stated plainly.
Delirium excluded before anything else
A sudden onset, fluctuating attention or a urinary infection would change the whole case, so a bedside delirium screen, a urinalysis and basic labs come first. Each result is reported, including the negative ones, because they license every later stage.
Medicines that may be the cause
Trihexyphenidyl and amantadine are both known to provoke hallucinations in Parkinson's disease. The analysis proposes withdrawing the anticholinergic first, as the least useful agent for his motor control, and records that the change would be made with his neurologist.
A cognitive score that matters
His MoCA of [23] suggests mild impairment, which raises the question of Parkinson's disease dementia and of a cholinesterase inhibitor. The analysis notes that rivastigmine carries an FDA approval for that dementia and treats it as a possible next step, not a given.
Three agents on four criteria
Pimavanserin, low-dose clozapine and quetiapine are scored on evidence, motor burden, monitoring and cost. The Movement Disorder Society's 2019 evidence review is cited for judging the trial support behind the first two stronger than that behind quetiapine.
A boxed warning read aloud
All three agents carry the class boxed warning: older adults with dementia-related psychosis face higher mortality on antipsychotics. The analysis quotes it, connects it to his borderline cognitive score, and records a discussion of that risk with him and his wife before any start.
Where marks go in MN665 Unit 2
Sequencing carries most of the grade here. Opening with the antipsychotic choice skips the two stages likeliest to resolve the case, a delirium screen and a medication review, and graders treat that as the analysis missing its own starting point. Any agent with strong dopamine blockade in Parkinson's disease draws a sharp comment, since the motor cost is predictable. Evidence claims get checked closely: overstating quetiapine's trial support, or presenting pimavanserin as risk-free, costs marks. The boxed warning should appear and be tied to his cognitive score rather than recited. If clozapine is the fallback, its blood monitoring has to be named. Unbracketed amounts, reductions planned without the neurologist and a spouse's account used with no note of his consent account for the smaller losses.
Get a MN665 Unit 2 example written to your instructions
Along with the rubric, send the Unit 2 case as your MN665 instructor wrote it, medication list and any cognitive scores included. Staged the way a clinician would have to act, with a stop point at each stage and the option comparison last, your first custom analysis arrives free in 24-48h.
MN665 Unit 2 questions, answered
Why does a complex case analysis delay the medication decision?
Because in cases like this one the first steps may make a new drug unnecessary. Excluding delirium and reducing medicines that provoke symptoms are cheaper and safer than adding an agent, and graders expect them to come first. Write each stage with the result that would end the sequence, so the order reads as reasoning rather than as a checklist.
Is it acceptable to recommend clozapine for an older adult?
In some cases, yes, when the evidence favors it and the monitoring is feasible. Low-dose clozapine has trial support in Parkinson's disease psychosis. State the blood count monitoring the label describes, the burden it places on the patient and family, and why it is or is not the right first choice here. Leaving the monitoring out is the error graders notice.
How should the analysis handle input from the patient's spouse?
Record it as collateral history and note that the patient agreed to its use where the case says so. A spouse frequently notices hallucinations or new beliefs first, and here the belief concerns her directly, which calls for care. Include her safety and support needs in the plan without treating her account as a substitute for his.